10/670,065
L/cook updated
12/19/07.

d his

(FILE 'HOME' ENTERED AT 08:46:19 ON 19 DEC 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 08:46:38 ON 19 DEC 2007

L1	0	S	(ANT VIMENTIN?)
L2	1698	S	(ANTI? VIMENTIN)
L3	3	S	L2 AND VACCINE?
L4	3		DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)
L5	766		DUPLICATE REMOVE L2 (932 DUPLICATES REMOVED)
L6	599	S	L5 AND PD<2003
L7	415	S	L6 AND HUMAN?
L8	4	S	L7 AND BACTER?
L9	10	S	L7 AND VIVO?
L10	0	S	(ANTI? VIMENTIN ADMIN?)
L11	0	S	(ADMIN? ANTI? VIMENTIN)
L12	485	S	(ANTI VIMENTIN ANTIBOD?)
L13	298	S	L12 AND HUMAN
L14	9	S	L12 AND ADMIN?
L15	6		DUPLICATE REMOVE L14 (3 DUPLICATES REMOVED)
L16	253	S	L13 AND PD<2003
L17	114		DUPLICATE REMOVE L16 (139 DUPLICATES REMOVED)
L18	0	S	(ADMIN? ANTI MRC5)
L19	0	S	(ANTI MRC5 ADMIN?)
L20	4	S	(ANTI MRC5)

d his

(FILE 'HOME' ENTERED AT 08:46:19 ON 19 DEC 2007)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 08:46:38 ON 19 DEC 2007

L1	0	S	(ANT VIMENTIN?)
L2	1698	S	(ANTI? VIMENTIN)
L3	3	S	L2 AND VACCINE?
L4	3		DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)
L5	766		DUPLICATE REMOVE L2 (932 DUPLICATES REMOVED)
L6	599	S	L5 AND PD<2003
L7	415	S	L6 AND HUMAN?
L8	4	S	L7 AND BACTER?
L9	10	S	L7 AND VIVO?
L10	0	S	(ANTI? VIMENTIN ADMIN?)
L11	0	S	(ADMIN? ANTI? VIMENTIN)
L12	485	S	(ANTI VIMENTIN ANTIBOD?)
L13	298	S	L12 AND HUMAN
L14	9	S	L12 AND ADMIN?
L15	6		DUPLICATE REMOVE L14 (3 DUPLICATES REMOVED)
L16	253	S	L13 AND PD<2003
L17	114		DUPLICATE REMOVE L16 (139 DUPLICATES REMOVED)
L18	0	S	(ADMIN? ANTI MRC5)
L19	0	S	(ANTI MRC5 ADMIN?)
L20	4	S	(ANTI MRC5)

ANSWER 61 OF 109 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1990:309962 BIOSIS

DN PREV199090028929; BA90:28929

TI IMMUNOGOLD STAINING OF INTERMEDIATE-SIZED FILAMENTS OF THE VIMENTIN TYPE IN HUMAN SKIN A POSTEMBEDDING IMMUNOELECTRON MICROSCOPIC STUDY.

AU RAPPERSBERGER K [Reprint author]; BINDER M; ZONZITS E; HORNICK U; WOLFF K

CS DEP DERMATOL I, UNIV VIENNA MED SCH, ALSER STRASSE 4, A-1090 VIENNA, AUSTRIA

SO Journal of Investigative Dermatology, (1990) Vol. 94, No. 5, pp. 700-705.
CODEN: JIDEAE. ISSN: 0022-202X.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 10 Jul 1990
Last Updated on STN: 10 Jul 1990

AB We have studied the localization of vimentin in normal human skin at the ultrastructural level using a monoclonal mouse anti-vimentin antibody and a postembedding immunogold-staining technique on thin sections of Lowicryl K4M embedded biopsies. Selective immunogold labeling of intermediate-sized filaments (IF) of epidermal Langerhans cells and melanocytes and of dermal fibroblasts was demonstrated. The IF of fibroblasts were more intensely stained than those of the epidermal dendritic cells; cell processes and dendrities of all three cell populations exhibited a greater number of IF and more pronounced immunogold-labeling than the perinuclear cytoplasm, relating IF of the vimentins type to dendrite formation and/or function. The method described is an appropriate tool for immunoelectron microscopic studies of IF of the vimentin type in situ.

CC Microscopy - Electron microscopy 01058
Cytology - Human 02508
Biochemistry studies - Proteins, peptides and amino acids 10064
Biochemistry studies - Carbohydrates 10068
Biochemistry studies - Minerals 10069
Anatomy and Histology - Microscopic and ultramicroscopic anatomy 11108
Integumentary system - Physiology and biochemistry 18504
Tissue culture, apparatus, methods and media 32500
Immunology - General and methods 34502

IT Major Concepts
Cell Biology; Integumentary System (Chemical Coordination and Homeostasis); Methods and Techniques; Morphology

IT Miscellaneous Descriptors
CELL ULTRASTRUCTURE MONOCLONAL ANTIBODY

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates, Vertebrates

ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1994:347274 BIOSIS

DN PREV199497360274

TI Immunodominant antigens of Streptococcus equisimilis shared by other beta-haemolytic streptococci.

AU Cimolai, N. [Reprint author]; Mah, D. G.

CS Dep. Pathol., British Columbia's Children's Hosp., 4480 Oak St., Vancouver, BC V6H 3V4, Canada

SO Journal of Medical Microbiology, (1994) Vol. 40, No. 5, pp. 323-329.
CODEN: JMMIAV. ISSN: 0022-2615.

DT Article

LA English

ED Entered STN: 8 Aug 1994
Last Updated on STN: 8 Aug 1994

AB Three immunodominant antigens of Streptococcus equisimilis (Lancefield group C) with approximate mol. wts of 46, 66 and 105 kDa were recognised by human serum IgG and IgA immunoblotting. These antigens were identified consistently by various human sera but immunoblots with IgA (heavy chain) and secretory IgA (J chain) from human respiratory secretions gave more variable results. Antigens with similar migration rates were demonstrated in S. pyogenes, large colony human biotype group G streptococci, and streptococci of groups C and G from the "S. anginosus-milleri group". Polyclonal antibody which was eluted from immunoblot substrates that contained the S. equisimilis 66-kDa antigen reacted with the 60-kDa antigen of S. pyogenes. Both polyclonal and monoclonal anti-vimentin antibodies identified the 46-kDa and 66-kDa antigens of S. equisimilis. The homology of these antigens among beta-haemolytic streptococci has the potential to complicate both a strategy for the utilization of immunoblotting for diagnostic purposes and the understanding of how such antigens may be involved in the pathogenesis of post-infectious sequelae.

CC Comparative biochemistry 10010
Biochemistry methods - Proteins, peptides and amino acids 10054
Biochemistry studies - Proteins, peptides and amino acids 10064
Biophysics - Methods and techniques 10504
Respiratory system - Pathology 16006
Physiology and biochemistry of bacteria 31000
Immunology - General and methods 34502
Immunology - Bacterial, viral and fungal 34504
Immunology - Immunopathology, tissue immunology 34508
Medical and clinical microbiology - General and methods 36001
Medical and clinical microbiology - Bacteriology 36002
Medical and clinical microbiology - Serodiagnosis 36504

IT Major Concepts
Biochemistry and Molecular Biophysics; Clinical Endocrinology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis); Infection; Physiology; Pulmonary Medicine (Human Medicine, Medical Sciences); Serology (Allied Medical Sciences)

IT Miscellaneous Descriptors
BETA-HEMOLYTIC; DIAGNOSTIC METHOD; DIAGNOSTIC SUITABILITY; GROUP C STREPTOCOCCI; IMMUNOBLOTTING; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC METHOD; PHARYNGITIS; POST-INFECTIOUS SEQUELAE PATHOGENESIS; SECRETORY IMMUNOGLOBULIN A; VIMENTIN

ORGN Classifier
Gram-Positive Cocci 07700

Super Taxa
Eubacteria; Bacteria; Microorganisms

Organism Name
gram-positive cocci
Streptococcus anginosus
Streptococcus equisimilis
Streptococcus milleri

Streptococcus pyogenes
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
Hominidae
Taxa Notes

ANSWER 2 OF 4 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 1994:347274 BIOSIS

DN PREV199497360274

TI Immunodominant antigens of Streptococcus equisimilis shared by other beta-haemolytic streptococci.

AU Cimolai, N. [Reprint author]; Mah, D. G.

CS Dep. Pathol., British Columbia's Children's Hosp., 4480 Oak St., Vancouver, BC V6H 3V4, Canada

SO Journal of Medical Microbiology, (1994) Vol. 40, No. 5, pp. 323-329.
CODEN: JMMIAV. ISSN: 0022-2615.

DT Article

LA English

ED Entered STN: 8 Aug 1994
Last Updated on STN: 8 Aug 1994

AB Three immunodominant antigens of Streptococcus equisimilis (Lancefield group C) with approximate mol. wts of 46, 66 and 105 kDa were recognised by human serum IgG and IgA immunoblotting. These antigens were identified consistently by various human sera but immunoblots with IgA (heavy chain) and secretory IgA (J chain) from human respiratory secretions gave more variable results. Antigens with similar migration rates were demonstrated in S. pyogenes, large colony human biotype group G streptococci, and streptococci of groups C and G from the "S. anginosus-milleri group". Polyclonal antibody which was eluted from immunoblot substrates that contained the S. equisimilis 66-kDa antigen reacted with the 60-kDa antigen of S. pyogenes. Both polyclonal and monoclonal anti-vimentin antibodies identified the 46-kDa and 66-kDa antigens of S. equisimilis. The homology of these antigens among beta-haemolytic streptococci has the potential to complicate both a strategy for the utilization of immunoblotting for diagnostic purposes and the understanding of how such antigens may be involved in the pathogenesis of post-infectious sequelae.

CC Comparative biochemistry 10010
Biochemistry methods - Proteins, peptides and amino acids 10054
Biochemistry studies - Proteins, peptides and amino acids 10064
Biophysics - Methods and techniques 10504
Respiratory system - Pathology 16006
Physiology and biochemistry of bacteria 31000
Immunology - General and methods 34502
Immunology - Bacterial, viral and fungal 34504
Immunology - Immunopathology, tissue immunology 34508
Medical and clinical microbiology - General and methods 36001
Medical and clinical microbiology - Bacteriology 36002
Medical and clinical microbiology - Serodiagnosis 36504

IT Major Concepts
Biochemistry and Molecular Biophysics; Clinical Endocrinology (Human Medicine, Medical Sciences); Immune System (Chemical Coordination and Homeostasis); Infection; Physiology; Pulmonary Medicine (Human Medicine, Medical Sciences); Serology (Allied Medical Sciences)

IT Miscellaneous Descriptors
BETA-HEMOLYTIC; DIAGNOSTIC METHOD; DIAGNOSTIC SUITABILITY; GROUP C STREPTOCOCCI; IMMUNOBLOTTING; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC METHOD; PHARYNGITIS; POST-INFECTIOUS SEQUELAE PATHOGENESIS; SECRETORY IMMUNOGLOBULIN A; VIMENTIN

ORGN Classifier
Gram-Positive Cocci 07700

Super Taxa
Eubacteria; Bacteria; Microorganisms

Organism Name
gram-positive cocci
Streptococcus anginosus
Streptococcus equisimilis
Streptococcus milleri

Streptococcus pyogenes
Taxa Notes
Bacteria, Eubacteria, Microorganisms
ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
Hominidae
Taxa Notes

ANSWER 9 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AN 2000429405 EMBASE

TI Phenotypic change of human cultured meningioma cells.

AU Pallini R.; Casalbore P.; Mercanti D.; Maggiano N.; Larocca L.M.

CS R. Pallini, Department of Neurosurgery, Catholic University, School of Medicine, Largo A. Gemelli 8, 00168 Rome, Italy. pallini@rm.unicatt.it

SO Journal of Neuro-Oncology, (2000) Vol. 49, No. 1, pp. 9-17.
Refs: 28
ISSN: 0167-594X CODEN: JNODD2

CY United States

DT Journal; Article

FS 022 Human Genetics
026 Immunology, Serology and Transplantation
029 Clinical and Experimental Biochemistry
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery

LA English

SL English

ED Entered STN: 21 Dec 2000
Last Updated on STN: 21 Dec 2000

AB One objection to using cell cultures for studying the proliferation of tumors is the potential for phenotypic changes that may occur in vitro. Here, we compared the antigen pattern expression of cultured meningioma cells with that of the primary tumor. Cell cultures established from 9 intracranial meningiomas and deparaffinized sections of the resected tumors were analyzed for immunophenotyping with the following antibodies: vimentin, cytokeratin , epithelial membrane antigen, S-100, neuron-specific enolase, synaptophisin, factor VIII-related antigen, CD4, CD31, CD34, CD45RB, CD68-PGM1, CD68-KP, and myeloid/histiocyte antigen (MAC387). Overall, the cultured meningioma cells retained the main feature of the primary tumor, being positive both for mesenchymal antigens and for epithelial antigens. Interestingly, the cultured meningioma cells abundantly expressed the CD68 antigens at early passage. The CD68 antigens, which are normally found on hematopoietic cells like macrophages and monocytes, were not detectable on meningioma cells in situ. Our results show that phenotypic changes on human meningioma cells may occur in vitro. This phenomenon suggests caution when transposing the in vitro results to the in vivo condition.

CT Medical Descriptors:
adult
aged
antigen expression
article
*cell proliferation
cell ultrastructure
clinical article
comparative anatomy
female
histopathology
human
human cell
human tissue
immunophenotyping
in vitro study
male
*meningioma
phenotype
tumor cell culture

CT Drug Descriptors:
CD31 antigen: EC, endogenous compound
CD34 antigen: EC, endogenous compound
CD4 antigen: EC, endogenous compound
CD45 antigen: EC, endogenous compound

*CD68 antigen: EC, endogenous compound
cytokeratin: EC, endogenous compound
epithelial membrane antigen: EC, endogenous compound
neuron specific enolase
protein S 100: EC, endogenous compound
synaptophysin
vimentin: EC, endogenous compound

ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1992:446261 CAPLUS
DN 117:46261
ED Entered STN: 08 Aug 1992
TI Species-specific recognition patterns of monoclonal antibodies directed against vimentin
AU Bohn, Wolfgang; Wiegers, Wolfram; Beuttenmueller, Michael; Traub, Peter
CS Heinrich-Pette-Inst. Exp. Virol. Immunol., Univ. Hamburg, Hamburg, D-2000/20, Germany
SO Experimental Cell Research (1992), 201(1), 1-7
CODEN: ECREAL; ISSN: 0014-4827
DT Journal
LA English
CC 15-3 (Immunochemistry)
AB Two com. available monoclonal antibodies raised against the intermediate filament protein vimentin were characterized concerning their species-specific reaction pattern on vertebrate cells. The antibody V9 exhibited extensive reactivity with vimentin of all mammalian species tested, but specifically did not detect vimentin in mouse cells and chicken fibroblasts. The antibody VIM 3B4 recognized vimentin in cells of chicken and most mammalian species, except for rodent species. Characterization of the binding site of VIM 3B4 on human vimentin by limited proteolysis and immunoblotting as well as by sequence comparison strongly suggested that the epitope is located in the coil 2 part of the vimentin rod domain. Site-directed mutagenesis of a mouse vimentin cDNA clone followed by in vivo expression showed that VIM 3B4 could detect rodent vimentin containing a single amino acid substitution (valine for leucine) at position 353 of the mouse vimentin sequence. Practical application for this finding was demonstrated by the unequivocal identification of a modified murine vimentin protein, distinct from the endogenous vimentin, in a cytoplasmic intermediate filament network in mouse skin fibroblasts transfected with a recombinant plasmid expression vector.
ST monoclonal antibody vimentin species specificity
IT Vimentins
RL: BIOL (Biological study)
(monoclonal antibodies to, species-specific recognition patterns of, in humans and laboratory animals)
IT Antibodies
RL: BIOL (Biological study)
(monoclonal, to vimentin, species-specific recognition patterns of, in humans and laboratory animals)

ANSWER 5 OF 114 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

AN 2002:612397 BIOSIS

DN PREV200200612397

TI Correlation of anti-vimentin antibodies with acute and chronic rejection following cardiac transplantation.

AU Danskine, Anna J. [Reprint author]; Smith, John D. [Reprint author]; Stanford, Rachel E. [Reprint author]; Newell, Helen [Reprint author]; Rose, Marlene L. [Reprint author]

CS NHLI, Imperial College School of Science, Technology and Medicine, Harefield Hospital, London, UK

SO Human Immunology, (2002) Vol. 63, No. Supplement 1, pp. S30. print.
Meeting Info.: 28th Annual Meeting of the American Society for Histocompatibility and Immunogenetics. Nashville, TN, USA. October 19-23, 2002. American Society for Histocompatibility and Immunogenetics.
CODEN: HUIMDQ. ISSN: 0198-8859.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; Report; (Meeting Report)

LA English

ED Entered STN: 27 Nov 2002
Last Updated on STN: 27 Nov 2002

CC General biology - Symposia, transactions and proceedings 00520
Cardiovascular system - Heart pathology 14506
Immunology - Immunopathology, tissue immunology 34508

IT Major Concepts
Cardiovascular Medicine (Human Medicine, Medical Sciences); Clinical Immunology (Human Medicine, Medical Sciences)

IT Chemicals & Biochemicals
antivimentin antibodies: acute cardiac graft rejection correlation, chronic cardiac graft rejection correlation

IT Methods & Equipment
cardiac transplantation: acute graft rejection, chronic graft rejection, transplantation method

IT Miscellaneous Descriptors
Meeting Abstract; Meeting Report

ORGN Classifier
Hominidae 86215
Super Taxa
Primates; Mammalia; Vertebrata; Chordata; Animalia
Organism Name
human: patient
Taxa Notes
Animals, Chordates, Humans, Mammals, Primates,

ANSWER 8 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1992:446261 CAPLUS
DN 117:46261
ED Entered STN: 08 Aug 1992
TI Species-specific recognition patterns of monoclonal antibodies directed against vimentin
AU Bohn, Wolfgang; Wiegers, Wolfram; Beuttenmueller, Michael; Traub, Peter
CS Heinrich-Pette-Inst. Exp. Virol. Immunol., Univ. Hamburg, Hamburg, D-2000/20, Germany
SO Experimental Cell Research (1992), 201(1), 1-7
CODEN: ECREAL; ISSN: 0014-4827
DT Journal
LA English
CC 15-3 (Immunochemistry)
AB Two com. available monoclonal antibodies raised against the intermediate filament protein vimentin were characterized concerning their species-specific reaction pattern on vertebrate cells. The antibody V9 exhibited extensive reactivity with vimentin of all mammalian species tested, but specifically did not detect vimentin in mouse cells and chicken fibroblasts. The antibody VIM 3B4 recognized vimentin in cells of chicken and most mammalian species, except for rodent species. Characterization of the binding site of VIM 3B4 on human vimentin by limited proteolysis and immunoblotting as well as by sequence comparison strongly suggested that the epitope is located in the coil 2 part of the vimentin rod domain. Site-directed mutagenesis of a mouse vimentin cDNA clone followed by in vivo expression showed that VIM 3B4 could detect rodent vimentin containing a single amino acid substitution (valine for leucine) at position 353 of the mouse vimentin sequence. Practical application for this finding was demonstrated by the unequivocal identification of a modified murine vimentin protein, distinct from the endogenous vimentin, in a cytoplasmic intermediate filament network in mouse skin fibroblasts transfected with a recombinant plasmid expression vector.
ST monoclonal antibody vimentin species specificity
IT Vimentins
RL: BIOL (Biological study)
(monoclonal antibodies to, species-specific recognition patterns of, in humans and laboratory animals)
IT Antibodies
RL: BIOL (Biological study)
(monoclonal, to vimentin, species-specific recognition patterns of, in humans and laboratory animals)

ANSWER 9 OF 10 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AN 2000429405 EMBASE

TI Phenotypic change of human cultured meningioma cells.

AU Pallini R.; Casalbore P.; Mercanti D.; Maggiano N.; Larocca L.M.

CS R. Pallini, Department of Neurosurgery, Catholic University, School of Medicine, Largo A. Gemelli 8, 00168 Rome, Italy. pallini@rm.unicatt.it

SO Journal of Neuro-Oncology, (2000) Vol. 49, No. 1, pp. 9-17.
Refs: 28
ISSN: 0167-594X CODEN: JNODD2

CY United States

DT Journal; Article

FS 022 Human Genetics
026 Immunology, Serology and Transplantation
029 Clinical and Experimental Biochemistry
005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery

LA English

SL English

ED Entered STN: 21 Dec 2000
Last Updated on STN: 21 Dec 2000

AB One objection to using cell cultures for studying the proliferation of tumors is the potential for phenotypic changes that may occur in vitro. Here, we compared the antigen pattern expression of cultured meningioma cells with that of the primary tumor. Cell cultures established from 9 intracranial meningiomas and deparaffinized sections of the resected tumors were analyzed for immunophenotyping with the following antibodies: vimentin, cytokeratin , epithelial membrane antigen, S-100, neuron-specific enolase, synaptophisin, factor VIII-related antigen, CD4, CD31, CD34, CD45RB, CD68-PGM1, CD68-KP, and myeloid/histiocyte antigen (MAC387). Overall, the cultured meningioma cells retained the main feature of the primary tumor, being positive both for mesenchymal antigens and for epithelial antigens. Interestingly, the cultured meningioma cells abundantly expressed the CD68 antigens at early passage. The CD68 antigens, which are normally found on hematopoietic cells like macrophages and monocytes, were not detectable on meningioma cells in situ. Our results show that phenotypic changes on human meningioma cells may occur in vitro. This phenomenon suggests caution when transposing the in vitro results to the in vivo condition.

CT Medical Descriptors:
adult
aged
antigen expression
article
*cell proliferation
cell ultrastructure
clinical article
comparative anatomy
female
histopathology
  human
  human cell
  human tissue
immunophenotyping
in vitro study
male
*meningioma
phenotype
tumor cell culture

CT Drug Descriptors:
CD31 antigen: EC, endogenous compound
CD34 antigen: EC, endogenous compound
CD4 antigen: EC, endogenous compound
CD45 antigen: EC, endogenous compound

*CD68 antigen: EC, endogenous compound
cytokeratin: EC, endogenous compound
epithelial membrane antigen: EC, endogenous compound
neuron specific enolase
protein S 100: EC, endogenous compound
synaptophysin
vimentin: EC, endogenous compound

April 2002

ANSWER 4 OF 114 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:450574 CAPLUS

DN 137:309136

ED Entered STN: 16 Jun 2002

TI Detection of anti-vimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia

AU Yang, Y.; Fujita, J.; Bandoh, S.; Ohtsuki, Y.; Yamadori, I.; Yoshinouchi, T.; Ishida, T.

CS First Department of Internal Medicine, Kagawa Medical University, Kagawa, 761-0793, Japan

SO Clinical and Experimental Immunology (2002), 128(1), 169-174
CODEN: CEXIAL; ISSN: 0009-9104

PB Blackwell Science Ltd.

DT Journal

LA English

CC 15-3 (Immunochemistry)
Section cross-reference(s): 14

AB It has been suggested that the humoral immune system plays a role in the pathogenesis of non-specific interstitial pneumonia (NSIP). Although some circulating autoantibodies to cytoskeletal protein(s) have been suggested, the antimyofibroblast antibody has not been investigated in patients with idiopathic pulmonary fibrosis (IPF) and NSIP. The purpose of this study is to evaluate the existence of antimyofibroblast antibody in the sera of patients with IPF and NSIP. The MRC5 cell line was used as a model of myofibroblast. The anti-MRC5 cell antibody was characterized in a patient with NSIP using Western blotting. Since we found that one of the anti-MRC5 antibodies was an anti-vimentin antibody, we established an ELISA to measure the levels of anti-vimentin antibody in the sera of patients with IPF (n = 12) and NSIP (n = 23). Initially, two anti-MRC5 cell antibodies were detected in the sera of patients with NSIP, one of which was characterized as the anti-vimentin antibody by Western blotting. The other was characterized as an anti-vimentin fragment antibody. We established an ELISA to measure the anti-vimentin antibody and found significantly higher levels in patients with IPF and NSIP than in normal volunteers. One of the anti-MRC5 cell antibodies in the serum of a patient with NSIP was against vimentin. The serum levels of anti-vimentin antibody were increased in patients with IPF and NSIP compared with that of normal volunteers. These results suggest that the anti-vimentin antibody may be involved in the process of lung injury in IPF and NSIP.

ST vimentin antibody idiopathic pulmonary fibrosis interstitial pneumonia

IT Antibodies and Immunoglobulins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(IgG autoantibodies; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Animal cell line
(MRC-5; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Human
(anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Vimentins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Lung, disease

ANSWER 4 OF 114 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:450574 CAPLUS
DN 137:309136
ED Entered STN: 16 Jun 2002
TI Detection of anti-vimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia
AU Yang, Y.; Fujita, J.; Bandoh, S.; Ohtsuki, Y.; Yamadori, I.; Yoshinouchi, T.; Ishida, T.
CS First Department of Internal Medicine, Kagawa Medical University, Kagawa, 761-0793, Japan
SO Clinical and Experimental Immunology (2002), 128(1), 169-174
CODEN: CEXIAL; ISSN: 0009-9104
PB Blackwell Science Ltd.
DT Journal
LA English
CC 15-3 (Immunochemistry)
Section cross-reference(s): 14
AB It has been suggested that the humoral immune system plays a role in the pathogenesis of non-specific interstitial pneumonia (NSIP). Although some circulating autoantibodies to cytoskeletal protein(s) have been suggested, the antimyofibroblast antibody has not been investigated in patients with idiopathic pulmonary fibrosis (IPF) and NSIP. The purpose of this study is to evaluate the existence of antimyofibroblast antibody in the sera of patients with IPF and NSIP. The MRC5 cell line was used as a model of myofibroblast. The anti-MRC5 cell antibody was characterized in a patient with NSIP using Western blotting. Since we found that one of the anti-MRC5 antibodies was an anti-vimentin antibody, we established an ELISA to measure the levels of anti-vimentin antibody in the sera of patients with IPF (n = 12) and NSIP (n = 23). Initially, two anti-MRC5 cell antibodies were detected in the sera of patients with NSIP, one of which was characterized as the anti-vimentin antibody by Western blotting. The other was characterized as an anti-vimentin fragment antibody. We established an ELISA to measure the anti-vimentin antibody and found significantly higher levels in patients with IPF and NSIP than in normal volunteers. One of the anti-MRC5 cell antibodies in the serum of a patient with NSIP was against vimentin. The serum levels of anti-vimentin antibody were increased in patients with IPF and NSIP compared with that of normal volunteers. These results suggest that the anti-vimentin antibody may be involved in the process of lung injury in IPF and NSIP.
ST vimentin antibody idiopathic pulmonary fibrosis interstitial pneumonia
IT Antibodies and Immunoglobulins
RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
(IgG autoantibodies; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)
IT Animal cell line
(MRC-5; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)
IT Human
(anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)
IT Vimentins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)
IT Lung, disease

(fibrosis; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Immunity
(humoral; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Pneumonia
(interstitial; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Fibroblast
(myofibroblast; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

IT Fibrosis
(pulmonary; anti-vimentin antibody against myofibroblasts in humans with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Alcover, A; Arthritis Rheum 1984, V27, P922 MEDLINE
(2) Alcover, A; Clin Exp Immunol 1985, V61, P24 CAPLUS
(3) American Thoracic Society; Am J Respir Crit Care Med 2000, V161, P646
(4) Bohme, M; Immunology 1986, V59, P583 MEDLINE
(5) Bretherton, L; Clin Immunol Immunopathol 1981, V18, P425 MEDLINE
(6) Casciola-Rosen, L; J Exp Med 1994, V179, P1317 CAPLUS
(7) Dobashi, N; Lung 2000, V178, P171 CAPLUS
(8) Dobashi, N; Thorax 1998, V53, P969 MEDLINE
(9) Fujita, J; Lung 1999, V177, P311 MEDLINE
(10) Fujita, J; Respir Med 1999, V93, P113 MEDLINE
(11) Gabbiani, G; Experientia 1971, V27, P549 MEDLINE
(12) Gensler, T; J Autoimmun 2001, V16, P59 MEDLINE
(13) Golan, T; J Clin Invest 1992, V90, P1067 MEDLINE
(14) Kataaha, P; Ann Rheum Dis 1985, V44, P446 MEDLINE
(15) Katzenstein, A; Am J Surg Pathol 1994, V18, P136 MEDLINE
(16) Kuhn, C; Am J Pathol 1991, V138, P1257 MEDLINE
(17) Kurki, P; J Rheumatol 1983, V10, P558 MEDLINE
(18) Laemmli, U; Nature 1970, V227, P680 CAPLUS
(19) Lazarides, E; Nature 1980, V283, P249 CAPLUS
(20) Mayet, W; Eur J Clin Invest 1990, V20, P516 MEDLINE
(21) Mevorach, D; J Exp Med 1998, V188, P387 CAPLUS
(22) Owen, P; Exp Cell Res 1996, V225, P366 CAPLUS
(23) Prasad, S; Biochem Biophys Res Commun 1998, V249, P332 CAPLUS
(24) Schmitt-Graff, A; Virchows Arch 1994, V425, P3 MEDLINE
(25) Senecal, J; Arthritis Rheum 1985, V28, P889 MEDLINE
(26) Senecal, J; J Clin Invest 1982, V69, P716 MEDLINE
(27) Skalli, O; Lab Invest 1989, V60, P275 MEDLINE
(28) Soldatenkov, V; Cell Death Differ 1998, V5, P307 CAPLUS
(29) Steinert, P; Ann Rev Biochem 1988, V57, P593 CAPLUS
(30) Suzuki, T; Jpn J Clin Immunol 1989, V12, P184
(31) Towbin, H; Proc Natl Acad Sci USA 1979, V76, P4350 CAPLUS
(32) Uchida, K; Ryumachi [in Japanese] 1987, V27, P356 MEDLINE
(33) Yoshinouchi, T; Eur Respir J 1999, V14, P579 MEDLINE
(34) Zhang, S; Lab Invest 1999, V79, P395 CAPLUS

(fibrosis; anti-vimentin antibody against
myofibroblasts in humans with idiopathic pulmonary fibrosis
and non-specific interstitial pneumonia)
IT Immunity
(humoral; anti-vimentin antibody against
myofibroblasts in humans with idiopathic pulmonary fibrosis
and non-specific interstitial pneumonia)
IT Pneumonia
(interstitial; anti-vimentin antibody
against myofibroblasts in humans with idiopathic pulmonary
fibrosis and non-specific interstitial pneumonia)
IT Fibroblast
(myofibroblast; anti-vimentin antibody
against myofibroblasts in humans with idiopathic pulmonary
fibrosis and non-specific interstitial pneumonia)
IT Fibrosis
(pulmonary; anti-vimentin antibody
against myofibroblasts in humans with idiopathic pulmonary
fibrosis and non-specific interstitial pneumonia)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Alcover, A; Arthritis Rheum 1984, V27, P922 MEDLINE
(2) Alcover, A; Clin Exp Immunol 1985, V61, P24 CAPLUS
(3) American Thoracic Society; Am J Respir Crit Care Med 2000, V161, P646
(4) Bohme, M; Immunology 1986, V59, P583 MEDLINE
(5) Bretherton, L; Clin Immunol Immunopathol 1981, V18, P425 MEDLINE
(6) Casciola-Rosen, L; J Exp Med 1994, V179, P1317 CAPLUS
(7) Dobashi, N; Lung 2000, V178, P171 CAPLUS
(8) Dobashi, N; Thorax 1998, V53, P969 MEDLINE
(9) Fujita, J; Lung 1999, V177, P311 MEDLINE
(10) Fujita, J; Respir Med 1999, V93, P113 MEDLINE
(11) Gabbiani, G; Experientia 1971, V27, P549 MEDLINE
(12) Gensler, T; J Autoimmun 2001, V16, P59 MEDLINE
(13) Golan, T; J Clin Invest 1992, V90, P1067 MEDLINE
(14) Kataaha, P; Ann Rheum Dis 1985, V44, P446 MEDLINE
(15) Katzenstein, A; Am J Surg Pathol 1994, V18, P136 MEDLINE
(16) Kuhn, C; Am J Pathol 1991, V138, P1257 MEDLINE
(17) Kurki, P; J Rheumatol 1983, V10, P558 MEDLINE
(18) Laemmli, U; Nature 1970, V227, P680 CAPLUS
(19) Lazarides, E; Nature 1980, V283, P249 CAPLUS
(20) Mayet, W; Eur J Clin Invest 1990, V20, P516 MEDLINE
(21) Mevorach, D; J Exp Med 1998, V188, P387 CAPLUS
(22) Owen, P; Exp Cell Res 1996, V225, P366 CAPLUS
(23) Prasad, S; Biochem Biophys Res Commun 1998, V249, P332 CAPLUS
(24) Schmitt-Graff, A; Virchows Arch 1994, V425, P3 MEDLINE
(25) Senecal, J; Arthritis Rheum 1985, V28, P889 MEDLINE
(26) Senecal, J; J Clin Invest 1982, V69, P716 MEDLINE
(27) Skalli, O; Lab Invest 1989, V60, P275 MEDLINE
(28) Soldatenkov, V; Cell Death Differ 1998, V5, P307 CAPLUS
(29) Steinert, P; Ann Rev Biochem 1988, V57, P593 CAPLUS
(30) Suzuki, T; Jpn J Clin Immunol 1989, V12, P184
(31) Towbin, H; Proc Natl Acad Sci USA 1979, V76, P4350 CAPLUS
(32) Uchida, K; Ryumachi [in Japanese] 1987, V27, P356 MEDLINE
(33) Yoshinouchi, T; Eur Respir J 1999, V14, P579 MEDLINE
(34) Zhang, S; Lab Invest 1999, V79, P395 CAPLUS

LYcook 12/19/07

PALM INTRANET

Day : Wednesday
Date: 12/19/2007
Time: 10:12:32

Biotech Query for 10/670065

Title: **METHODS OF SECRETORY VIMENTIN DETECTION AND MODULATION**

Inventor: **MARKOVITZ, DAVID**

Location:

Location Date: Group Art Unit: **1641**

Status: **71/RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER**

Barcode: Filing or 371(c) Date: **09/24/2003**

Num	Date	Code	Contents Description
28	12/04/2006	CRFE	CRF IS GOOD TECHNICALLY / ENTERED INTO DATABASE

Search for Biotech Info: **Application#** [ ] Search

PCT / [ ] / [ ] Search

Bar Code # [ ] Search

To go back, right click here and select Back. To go forward, right click here and select Forward. To refresh, right click here and select Refresh.
Back to OASIS | Home page

LYCook 12/19/07

PALM Intranet

Application Number [ ] Submit

IDS Flag Clearance for Application 10670065

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Last Modified	Reviewer
WIDS	2007-10-05	38	Y ☑	2007-12-19 10:12:14.0	LCook
WIDS	2006-07-17	25	Y ☑	2007-05-09 00:00:00.0	CR #232884
Update					